ARTICLE | Clinical News
Eloctate regulatory update
October 5, 2015 7:00 AM UTC
EMA’s CHMP recommended approval of Elocta from Biogen for treatment and prophylaxis of bleeding in patients with hemophilia A. The long-acting recombinant fusion protein consisting of the Fc domain of...